Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Waiting For Next Regulatory Shoe To Drop For Takeda's Gout Drug Uloric

Mar 30 2018

• By Emily Hayes

WarningSign_1200x675

Related Content

CV Trials For Symptomatic Conditions Feasible But Not Always Practical, FDA Panel Says

Jun 23 2014

TAP To Discuss Gout Treatment With FDA Following Second “Approvable” Letter

Aug 11 2006

Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?

Dec 01 2008

Takeda Positions Uloric To Gout Patients In Need Of Better Control

Feb 23 2009

Related Companies

Takeda Pharmaceutical Co. Ltd.

Additional Topics

United States Drug Safety Advisory Committees Regulation Cardiovascular Immune Disorders BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window